After a negative article at Smartmoney.com about Generex Biotech, the stock has bounced back slightly, up over $3.00 today. The article is quite damning, claiming that Generex is simply a company with joke clinical trials of it's oral insulin in Equador and very bad cash burn rate. I really want to like the prospects of this company's oral insulin product, and I predict, without anymore bad news this week, that shares should be over $3.50 by the end of the week. I can't recommend buying it until the dust clears however.
Technorati Tags: investing, finance, money